0001193125-26-182257.txt : 20260427 0001193125-26-182257.hdr.sgml : 20260427 20260427163913 ACCESSION NUMBER: 0001193125-26-182257 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20260427 FILED AS OF DATE: 20260427 DATE AS OF CHANGE: 20260427 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Castelli Jeff CENTRAL INDEX KEY: 0001569225 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-33497 FILM NUMBER: 26901634 MAIL ADDRESS: STREET 1: 1 CEDAR BROOK DRIVE CITY: CRANBURY STATE: NJ ZIP: 08512 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: AMICUS THERAPEUTICS, INC. CENTRAL INDEX KEY: 0001178879 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 200422823 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 47 HULFISH STREET CITY: PRINCETON STATE: NJ ZIP: 08542 BUSINESS PHONE: (609) 662-2000 MAIL ADDRESS: STREET 1: 47 HULFISH STREET CITY: PRINCETON STATE: NJ ZIP: 08542 FORMER COMPANY: FORMER CONFORMED NAME: AMICUS THERAPEUTICS INC DATE OF NAME CHANGE: 20020729 4 1 ownership.xml 4 X0609 4 2026-04-27 true 0001178879 AMICUS THERAPEUTICS, INC. FOLD 0001569225 Castelli Jeff false 47 HULFISH STREET PRINCETON NJ 08542 false true false false Chief Development Officer false Common Stock 2026-04-27 4 D false 427089 14.50 D 0 D Stock Options (right to buy) 10.04 2026-04-27 4 D false 82644 D 2029-01-02 Common Stock 82644 0 D Stock Options (right to buy) 9.55 2026-04-27 4 D false 107575 D 2030-01-02 Common Stock 107575 0 D Stock Options (right to buy) 12.11 2026-04-27 4 D false 108266 D 2032-01-03 Common Stock 108266 0 D Stock Options (right to buy) 11.93 2026-04-27 4 D false 125462 D 2033-01-03 Common Stock 125462 0 D Stock Options (right to buy) 14.24 2026-04-27 4 D false 99073 D 2034-01-02 Common Stock 99073 0 D Stock Options (right to buy) 9.41 2026-04-27 4 D false 150517 D 2035-01-03 Common Stock 150517 0 D The reported securities were disposed of in connection with consummation of the acquisition of the Issuer by BioMarin Pharmaceutical Inc. (the "Merger"), which included 318,417 shares of Common Stock and 108,672 restricted stock units (which vested in full in connection with consummation of the Merger). In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. Each Option was fully vested. Each Option vested in full in connection with consummation of the Merger. /s/ Christian Formica, Attorney-in-Fact 2026-04-27